Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours

Combined ridaforolimus and MK-0752 showed activity in HNSCC. However, a high number of adverse events were reported at the MTD, which would require careful management during future clinical development.